IGF2BP3 and triple-negative breast carcinoma: And digestive tumor research can reference its mechanisms elsewhere, e.g., metastasis inhibition via circNAV3/miR-4262/ST6GALNAC5/EGFR (as in triple-negative breast cancer) (Xie et al., 2025) or progression suppression through m6A/IGF2BP3-stabilized TWIST1 mRNA (Cui et al., 2022).